Potent antibody drug conjugates for cancer therapy

Current Opinion in Chemical Biology

Volumn 13, Issue 3, 2009, Pages 235-244

  Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; AURISTATIN DERIVATIVE; AVE 9633; CALICHEAMICIN; CAMPTOTHECIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; MAYTANSINE; MAYTANSINOID DERIVATIVE; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR96; MONOCLONAL ANTIBODY SGN 35; MONOMETHYL AURISTATIN E; TALLYSOMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VALYLCITRULLINE MONOMETHYL AURISTATIN E; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER THERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; EPITHELIUM TUMOR; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; LARGE CELL LYMPHOMA; LIVER VEIN OBSTRUCTION; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; THROMBOCYTOPENIA; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOTOXINS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 67649886201     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.03.023     Document Type: Review

References (74)

1. Reichert J.M., Rosensweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat Biotechnol 23 9 (2005) 1073-1078
2. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6 5 (2007) 349-356. An interesting update on mAb based therapy for cancer treatment.
3. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41 1 (2008) 98-107
4. Damle N.K. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4 9 (2004) 1445-1452
5. Kovtun Y.V., and Goldmacher V.S. Cell killing by antibody-drug conjugates. Cancer Lett 255 2 (2007) 232-240
6. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23 9 (2005) 1137-1146. A comprehensive review on critical issues in conjugated mAbs for therapy and imaging.
7. Pietersz G.A., et al. Chemoimmunoconjugates for the treatment of cancer. Adv Immunol 56 (1994) 301-387
8. Trail P.A., King H.D., and Dubowchik G.M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52 5 (2003) 328-337
9. Trail P.A., et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261 5118 (1993) 212-215
10. Saleh M.N., et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 18 11 (2000) 2282-2292
11. Tolcher A.W., et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17 2 (1999) 478-484
12. Damle N.K., and Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 3 4 (2003) 386-390
13. Boghaert E.R., et al. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 mul) blood samples. Cancer Chemother Pharmacol 61 6 (2008) 1027-1035
14. Y-positive human carcinoma cells and xenografts. Clin Cancer Res 10 13 (2004) 4538-4549
15. Boghaert E.R., et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol 32 1 (2008) 221-234
16. Hamann P.R., et al. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug Chem 16 2 (2005) 346-353
17. Trail P.A., et al. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res 57 1 (1997) 100-105
18. DiJoseph J.F., et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103 5 (2004) 1807-1814
19. DiJoseph J.F., et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 10 24 (2004) 8620-8629
20. DiJoseph J.F., et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 54 1 (2005) 11-24
21. Bross P.F., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7 6 (2001) 1490-1496
22. Hamann P.R., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13 1 (2002) 47-58
23. Larson R.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 7 (2005) 1442-1452
24. Boghaert E.R., et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 28 3 (2006) 675-684
25. Jedema I., et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18 2 (2004) 316-325
26. Doronina S.O., et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17 1 (2006) 114-124
27. Doronina S.O., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21 7 (2003) 778-784
28. Thorpe P.E., et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 48 22 (1988) 6396-6403
29. Thorpe P.E., et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res 47 22 (1987) 5924-5931
30. Widdison W.C., et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49 14 (2006) 4392-4408
31. Kovtun Y.V., et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66 6 (2006) 3214-3221
32. Liu C., et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 93 16 (1996) 8618-8623
33. v integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res 13 12 (2007) 3689-3695
34. Aboukameel A., et al. Superior anti-tumor activity of the CD19-directed immunotoxin. SAR3419 to rituximab in non-Hodgkin's xenograft animal models: preclinical evaluation. Blood 110 (2007) (p. Abstract 2339)
35. Henry M.D., et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64 21 (2004) 7995-8001
36. Legrand O., et al. An open label, dose escalation study of AVE9633 administered as a single agent by intravenous (IV) infusion weekly for 2 weeks in 4-week cycle to patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML). Blood 110 (2007) (p. Abstract 1850)
37. Polson A.G., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and Linker-Drug Selection. Cancer Res 69 6 (2009) 2358-2364
38. Tassone P., et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104 12 (2004) 3688-3696
39. Tassone P., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 64 13 (2004) 4629-4636
40. Dubowchik G.M., and Firestone R.A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 8 23 (1998) 3341-3346
41. Dubowchik G.M., et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett 8 23 (1998) 3347-3352
42. Walker M.A., et al. Synthesis of an immunoconjugate of camptothecin. Bioorg Med Chem Lett 12 2 (2002) 217-219
43. Walker M.A., et al. Monoclonal antibody mediated intracellular targeting of tallysomycin S(10b). Bioorg Med Chem Lett 14 16 (2004) 4323-4327
44. Francisco J.A., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102 4 (2003) 1458-1465
45. Sanderson R.J., et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11 2 Pt 1 (2005) 843-852
46. Ryan M.C., et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 6 11 (2007) 3009-3018
47. Benjamin D, et al.: Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 2007: p. Abstract B60.
48. Law C.L., et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10 23 (2004) 7842-7851
49. Law C.L., et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66 4 (2006) 2328-2337
50. Bhaskar V., et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 63 19 (2003) 6387-6394
51. Mao W., et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 64 3 (2004) 781-788
52. Tse K.F., et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12 4 (2006) 1373-1382
53. Chen Y., et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 67 10 (2007) 4924-4932
54. Ma D., et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12 8 (2006) 2591-2596
55. Afar D.E., et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 3 8 (2004) 921-932
56. Erickson H.K., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66 8 (2006) 4426-4433
57. Alley S.C., et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19 3 (2008) 759-765
58. King H.D., et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem 45 19 (2002) 4336-4343
59. Hollander I., Kunz A., and Hamann P.R. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem 19 1 (2008) 358-361
60. Hamblett K.J., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10 20 (2004) 7063-7070
61. Younes A., et al.: A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study. 7th International Symposium on Hodgkin Lymphoma 2007: p. Abstract PO99bis.
62. Younes A., et al.: Objective responses in a Phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. American Society of Clinical Oncology 2008: p. Abstract 8526. This demonstrates clinical utility of an advanced ADC in treating drug refractive human cancers
63. McDonagh C.F., et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19 7 (2006) 299-307
64. Sun M.M., et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16 5 (2005) 1282-1290
65. Junutula J.R., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008)
66. Beeram M., et al. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). J Clin Oncol 25 18S (2007) (p. Abstract 1042). This demonstrates the clinical utility of an ADC for treating refractive breast cancer.
67. Krop IE, et al.: A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. 30th Annual San Antonio Breast Cancer Symposium 2007: p. Abstract 310.
68. Pollack V.A., et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60 3 (2007) 423-435
69. Sznol M., et al.: Phase I pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 2007: p. Abstract B47.
70. Sievers E.L. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1 5 (2001) 893-901
71. Dijoseph J.F., et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21 11 (2007) 2240-2245
72. Mita M.M., et al. A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J Clin Oncol 25 18S (2007) (p. Abstract 3062)
73. Chanan-Khan A.A., et al. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. Blood 110 (2007) (p. Abstract 1174)
74. McCann J., et al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 25 18S (2007) (p. Abstract 18084)